z-logo
Premium
Prevalence of MYH germline mutations in Swiss APC mutation‐negative polyposis patients
Author(s) -
Russell Anna M.,
Zhang Jian,
Luz Judith,
Hutter Pierre,
Chappuis Pierre O.,
Berthod Claudine Rey,
Maillet Philippe,
Mueller Hansjakob,
Heinimann Karl
Publication year - 2005
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.21470
Subject(s) - mutyh , germline mutation , adenomatous polyposis coli , mutation , familial adenomatous polyposis , cancer research , germline , medicine , genetics , biology , colorectal cancer , cancer , gene
In 10–30% of patients with classical familial adenomatous polyposis (FAP) and up to 90% of those with attenuated (<100 colorectal adenomas; AFAP) polyposis, no pathogenic germline mutation in the adenomatous polyposis coli ( APC ) gene can be identified ( APC mutation‐negative). Recently, biallelic mutations in the base excision repair gene MYH have been shown to predispose to a multiple adenoma and carcinoma phenotype. This study aimed to ( i ) assess the MYH mutation carrier frequency among Swiss APC mutation‐negative patients and ( ii ) identify phenotypic differences between MYH mutation carriers and APC/MYH mutation‐negative polyposis patients. Seventy‐nine unrelated APC mutation‐negative Swiss patients with either classical ( n = 18) or attenuated ( n = 61) polyposis were screened for germline mutations in MYH by dHPLC and direct genomic DNA sequencing. Overall, 7 (8.9%) biallelic and 9 (11.4%) monoallelic MYH germline mutation carriers were identified. Among patients with a family history compatible with autosomal recessive inheritance ( n = 45), 1 (10.0%) out of 10 classical polyposis and 6 (17.1%) out of 35 attenuated polyposis patients carried biallelic MYH alterations, 2 of which represent novel gene variants (p.R171Q and p.R231H). Colorectal cancer was significantly ( p < 0.007) more frequent in biallelic mutation carriers (71.4%) compared with that of monoallelic and MYH mutation‐negative polyposis patients (0 and 13.8%, respectively). On the basis of our findings and earlier reports, MYH mutation screening should be considered if all of the following criteria are fulfilled: ( i ) presence of classical or attenuated polyposis coli, ( ii ) absence of a pathogenic APC mutation, and ( iii ) a family history compatible with an autosomal recessive mode of inheritance. © 2005 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom